Testing effectiveness (Phase 2)Study completedNCT05299125
What this trial is testing
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
Who this might be right for
Metastatic Non-small Cell Lung Cancers
Latin American Cooperative Oncology Group 54